Hodgkin Disease

"Hodgkin Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.

Descriptor ID	D006689
MeSH Number(s)	C04.557.386.355 C15.604.515.569.355 C20.683.515.761.355
Concept/Terms	Hodgkin Disease Hodgkin Disease Disease, Hodgkin Granuloma, Hodgkin's Hodgkin's Granuloma Granuloma, Hodgkins Hodgkins Granuloma Lymphogranuloma, Malignant Lymphogranulomas, Malignant Malignant Lymphogranuloma Malignant Lymphogranulomas Hodgkin Lymphoma Lymphoma, Hodgkin Hodgkin's Disease Disease, Hodgkin's Hodgkin's Lymphoma Hodgkins Lymphoma Lymphoma, Hodgkin's Hodgkins Disease Disease, Hodgkins Granuloma, Hodgkin Hodgkin Granuloma Granuloma, Malignant Malignant Granuloma Malignant Granulomas Nodular Lymphocyte-Predominant Hodgkin's Lymphoma Nodular Lymphocyte-Predominant Hodgkin's Lymphoma Nodular Lymphocyte Predominant Hodgkin's Lymphoma Nodular Sclerosing Hodgkin's Lymphoma Lymphocyte-Rich Classical Hodgkin's Lymphoma Lymphocyte-Rich Classical Hodgkin's Lymphoma Lymphocyte Rich Classical Hodgkin's Lymphoma Mixed Cellularity Hodgkin's Lymphoma Mixed Cellularity Hodgkin's Lymphoma Hodgkin Lymphoma, Adult Hodgkin Lymphoma, Adult Adult Hodgkin Lymphoma Lymphocyte Depletion Hodgkin's Lymphoma Lymphocyte Depletion Hodgkin's Lymphoma

Below are MeSH descriptors whose meaning is more general than "Hodgkin Disease".

Diseases [C]
Neoplasms [C04]
Neoplasms by Histologic Type [C04.557]
Lymphoma [C04.557.386]
Hodgkin Disease [C04.557.386.355]
Hemic and Lymphatic Diseases [C15]
Lymphatic Diseases [C15.604]
Lymphoproliferative Disorders [C15.604.515]
Lymphoma [C15.604.515.569]
Hodgkin Disease [C15.604.515.569.355]
Immune System Diseases [C20]
Immunoproliferative Disorders [C20.683]
Lymphoproliferative Disorders [C20.683.515]
Lymphoma [C20.683.515.761]
Hodgkin Disease [C20.683.515.761.355]

Below are MeSH descriptors whose meaning is related to "Hodgkin Disease".

Below are MeSH descriptors whose meaning is more specific than "Hodgkin Disease".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Hodgkin Disease" by people in this website by year, and whether "Hodgkin Disease" was a major or minor topic of these publications.

Bar chart showing 505 publications over 31 distinct years, with a maximum of 31 publications in 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1992	8	2	10
1993	10	0	10
1994	9	1	10
1995	8	1	9
1996	9	1	10
1997	14	2	16
1998	11	2	13
1999	5	2	7
2000	6	3	9
2001	7	2	9
2002	15	2	17
2003	18	1	19
2004	15	2	17
2005	10	4	14
2006	23	3	26
2007	14	0	14
2008	16	5	21
2009	10	2	12
2010	11	3	14
2011	18	0	18
2012	18	2	20
2013	18	1	19
2014	15	0	15
2015	19	3	22
2016	29	2	31
2017	24	4	28
2018	27	2	29
2019	13	4	17
2020	20	0	20
2021	20	2	22
2022	7	0	7

Below are the most recent publications written about "Hodgkin Disease" by people in Profiles.

Evens AM, Connors JM, Younes A, Ansell SM, Kim WS, Radford J, Feldman T, Tuscano J, Savage KJ, Oki Y, Grigg A, Pocock C, Dlugosz-Danecka M, Fenton K, Forero-Torres A, Liu R, Jolin H, Gautam A, Gallamini A. Older patients (aged =60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. Haematologica. 2022 05 01; 107(5):1086-1094.

View in: PubMed
Nieto Y, Gruschkus S, Valdez BC, Jones RB, Anderlini P, Hosing C, Popat U, Qazilbash M, Kebriaei P, Alousi A, Saini N, Srour S, Rezvani K, Ramdial J, Barnett M, Gulbis A, Shigle TL, Ahmed S, Iyer S, Lee H, Nair R, Parmar S, Steiner R, Dabaja B, Pinnix C, Gunther J, Cuglievan B, Mahadeo K, Khazal S, Chuang H, Champlin R, Shpall EJ, Andersson BS. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. Haematologica. 2022 04 01; 107(4):899-908.

View in: PubMed
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, Benitez CM, Chen W, Dabaja B, Daly ME, Gordon LI, Hansen N, Herrera AF, Hochberg EP, Johnston PB, Kaminski MS, Kelsey CR, Kenkre VP, Khan N, Lynch RC, Maddocks K, McConathy J, Metzger M, Morgan D, Mulroney C, Pullarkat ST, Rabinovitch R, Rosenspire KC, Seropian S, Tao R, Torka P, Winter JN, Yahalom J, Yang JC, Burns JL, Campbell M, Sundar H. NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022. J Natl Compr Canc Netw. 2022 04; 20(4):322-334.

View in: PubMed
de Armas S, Huertas-Ayala C, Chan RY, Chi YY, Huh WW, Termuhlen A, Gaynon PS, Kovach AE, Doan A. Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution. Pediatr Blood Cancer. 2022 05; 69(5):e29601.

View in: PubMed
Johnston RL, Mottok A, Chan FC, Jiang A, Diepstra A, Visser L, Telenius A, Gascoyne RD, Friedman DL, Schwartz CL, Kelly KM, Scott DW, Horton TM, Steidl C. A gene expression-based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma. Blood. 2022 02 10; 139(6):889-893.

View in: PubMed
Friend BD, Muhsen IN, Patel S, Hill LC, Lulla P, Ramos CA, Pingali SR, Kamble RT, John TD, Salem B, Bhar S, Doherty EE, Craddock J, Sasa G, Wu M, Wang T, Martinez C, Krance RA, Heslop HE, Carrum G. Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplant. 2022 04; 57(4):579-585.

View in: PubMed
Kahn JM, Pei Q, Friedman DL, Kaplan J, Keller FG, Hodgson D, Wu Y, Appel BE, Bhatia S, Henderson TO, Schwartz CL, Kelly KM, Castellino SM. Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children's oncology group trials. Lancet Haematol. 2022 Jan; 9(1):e49-e57.

View in: PubMed
Kleinschmidt-DeMasters BK, Marshall CB, Cykowski MD. Paraneoplastic Lower Motor Neuron Disease. J Neuropathol Exp Neurol. 2021 12 29; 80(12):1125-1127.

View in: PubMed
Zhang Q, Kim DH, Xu Y, Wang W, Medeiros LJ. Clinicopathological features of syncytial variant nodular sclerosis Hodgkin lymphoma. Hum Pathol. 2022 01; 119:105-113.

View in: PubMed
Milgrom SA, Bakst RL, Campbell BA. Clinical Outcomes Confirm Conjecture: Modern Radiation Therapy Reduces the Risk of Late Toxicity in Survivors of Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys. 2021 11 15; 111(4):841-850.

View in: PubMed

People

Explore

Similar Concepts

Top Journals